Transcatheter valve replacement in the bicuspid valve is increasingly performed, but challenges remain

Transcatheter Valve Replacement in the Bicuspid Valve Is Increasingly Performed, but Challenges RemainAs experience increases, transcatheter aortic valve replacement (TAVR) has expanded to different populations and anatomies. This study sought to compare technical and clinical outcomes in patients with bicuspid versus tricuspid aortic stenosis from the Bicuspid AS TAVR Multicenter Registry.

 

Outcomes of 561 patients with bicuspid valves and 4546 patients with tricuspid valves were compared. Propensity score matching was used due to baseline differences, assembling 546 pairs of patients with similar baseline characteristics except for valve anatomy.

 

Patients who received bicuspid valves had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and significantly lower device success rates (85.3% vs. 91.4%; p = 0.002).

 

A group of 320 patients with bicuspid aortic stenosis received first-generation valves (Sapiens XT and CoreValve) and presented recurrent aortic root injury with balloon-expandable devices (4.5% vs. 0.0%; p = 0.015) and more frequent moderate-to-severe paravalvular leak with self-expandable devices (19.4% vs. 10.5%; p = 0.02).

 

Among patients with second-generation devices (Sapiens 3, Evolut R, and Lotus), results with bicuspid and tricuspid valves were comparable.

 

The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid valves (17.2% 19.4%; p = 0.28).

 

Conclusion

Compared with patients who received tricuspid valves, transcatheter aortic valve replacement in patients who received bicuspid valves was associated with a similar prognosis, but lower device success rates. There were outcome differences in patients treated with first-generation balloon-expandable and self-expandable devices, whereas no differences were observed with second-generation devices.

 

Editorial

In this study, patients with bicuspid aortic stenosis were younger and presented less comorbidities than patients with tricuspid stenosis, and these differences required the use of propensity score matching.

 

Given the shift towards treating younger and lower surgical-risk patients with TAVR, the proportion of patients with bicuspid aortic stenosis assessed for valve replacement is likely to increase.

 

New devices have managed to limit differences between bicuspid and tricuspid stenosis, although the technical challenge will always be higher.

 

Original title: Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2017;69:2579-89.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...